 Shares of argenx NASDAQ: ARGX, a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. An impressive 67.7 of those treated with efgartigimod achieved improvements on their myasthenia gravis activities of daily living MG-ADL scores of at least two points. Myasthenia gravis is a relatively rare immune disorder that weakens patients by jamming up the transmission of signals between their brains and their muscle fibers. 